ImmuneOnco banks on cutting-edge cancer drugs to attract IPO cash
The biopharma wants to use IPO proceeds to bring its cancer immunotherapies to market, having already built a lofty valuation with backers such as Eli Lilly Key Takeaways: ImmuneOnco’s main…
